MAPT and Alzheimer disease: For this, we studied human-post mortem, symptomatic AD cases without and with TDP-43 pathology: AD(LATE-NC-) and AD(LATE-NC+), respectively, and we used in vitro and in vivo approaches to investigate the synergy between TDP-43 and p-tau on a functional level.